Peer Review | Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials
Abstract As cancer immunotherapies continue to expand across all areas of oncology, it is imperative to establish a standardized approach for defining and capturing clinically important toxicities, such as cytokine release syndrome (CRS). In this paper, we provide considerations for categorizing the variety of adverse events that may accompany CRS and for recognizing that presentations…